Shares of Viatris Inc. (VTRS) plummeted over 20% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results and weaker-than-expected guidance for 2025.
The pharmaceutical giant reported adjusted earnings per share of $0.54 for Q4 2024, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking a year-over-year decline of 8.13%.
The company's 2025 outlook also fell short of market expectations. Viatris forecast 2025 revenue between $13.5 billion and $14 billion, below analysts' estimates of $14.27 billion. Furthermore, the company expects 2025 adjusted earnings per share between $2.12 and $2.26, compared with estimates of $2.59.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.